Elevai Labs Inc.

ELAB

US28622K1043

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
0.6501 ^USD	+3.19%		-4.80%	-64.44%

May. 02	Elevai Biosciences Inc. Highlights Preclinical Data Showing Potential of In-Licensed Asset ?EL-22? for The Treatment of Obesity	CI
May. 01	Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries	CI

Elevai Labs, Inc. announced that it has received $0.75 million in funding

March 16, 2023

On March 17, 2023, Elevai Labs, Inc. closed the transaction. The company has received $750,000 in transaction from a single investor.

Latest news about Elevai Labs Inc.

Elevai Biosciences Inc. Highlights Preclinical Data Showing Potential of In-Licensed Asset ?EL-22? for The Treatment of Obesity	May. 02	CI
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries	May. 01	CI
Elevai Labs Inc. Announces Executive Changes	May. 01	CI
Elevai Labs Enters into Exclusive Licensing Agreement with MOA Life Plus Co., Ltd to Develop and Commercialize Two Novel Assets for the Treatment of Obesity and Muscle Loss Prevention	May. 01	CI
Elevai Labs Signs Exclusive Distribution Deal for Taiwan	Apr. 22	MT
Elevai Labs, Inc. Enters the Taiwan Market with Signing of 5Th International Distribution Agreement in 14 Months	Apr. 22	CI
Elevai Labs, Inc. Launches E-Commerce Portal	Mar. 18	CI
Elevai Labs, Inc. Announces Board Changes	Mar. 07	CI
Elevai Labs, Inc. signed a license agreement to acquire a Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology from INmune Bio, Inc..	Jan. 15	CI
Elevai Labs, Inc. Announces New Partnership with Skin Sana Ltd	Dec. 07	CI
Elevai Labs, Inc. Enters into Licensing Agreement with Yuva Biosciences, Inc. to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products	Nov. 29	CI
Sector Update: Health Care Stocks Higher Friday Afternoon	Nov. 24	MT
Elevai Labs Closes IPO, Raises $6 Million	Nov. 24	MT
Elevai Labs, Inc. announced that it has received $0.75 million in funding	23-03-16	CI
Elevai Labs, Inc. announced a financing transaction	23-03-01	CI

Elevai Labs, Inc. is a physician-dispensed skincare company. The Company conducts research and development to advance science-driven topical skincare that complements the medical aesthetics industry. It produces and commercializes topical skincare products that contain its proprietary stem cell derived Elevai Exosomes designed to enhance the appearance of skin. Its Precision Regenerative Exosome Technology (PREx) biotechnology process yields exosome lots from human umbilical cord-derived mesenchymal stem cells (hUMSC) for its specialty physician-dispensed skincare product lines. It has integrated the use of stem cell exosomes into its initial product line: Elevai Post Treatment E-Series. The E-Series comprises two post-skincare procedure care products that target the face and neck, and upper chest regions. Its products include Empower and Enfinity serums. Empower is its after-treatment topical product that supports the appearance of healthy skin and promotes an even toned complexion.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ELEVAI LABS INC.	-64.44%	11.27M
MODERNA, INC.	+33.37%	50.85B
IQVIA HOLDINGS INC.	+1.55%	42.82B
LONZA GROUP AG	+49.22%	42.03B
CELLTRION, INC.	-4.22%	29.55B
ICON PUBLIC LIMITED COMPANY	+11.57%	26.11B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	19.13B
BIO-TECHNE CORPORATION	+7.36%	13.05B
MEDPACE HOLDINGS, INC.	+28.30%	12.16B
UNITED THERAPEUTICS CORPORATION	+23.80%	12.08B

Other Biotechnology & Medical Research

Elevai Labs Inc.

Equities

ELAB

US28622K1043

Biotechnology & Medical Research

Elevai Labs, Inc. announced that it has received $0.75 million in funding

Latest news about Elevai Labs Inc.

Chart Elevai Labs Inc.

Company Profile

Income Statement Evolution

Sector Other Biotechnology & Medical Research